NCT02077374View on ClinicalTrials.gov

A Study of IDN-6556 in Subjects With NAFLD and Raised Transaminases

PHASE2CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2015

Conditions
Nonalcoholic SteatohepatitisNon-alcoholic Fatty Liver Disease
Interventions
DRUG

IDN-6556

25 mg BID for 28 days

OTHER

Placebo

Placebo BID for 28 Days

Trial Locations (7)

23226

Bon Secours St. Mary's Hospital, Richmond

23602

Mary Immaculate Hospital, Newport News

33136

University of Miami, Miami

46202

Indiana University, Indianapolis

48202

Henry Ford Hospital, Detroit

55905

Mayo Clinic Rochester, Rochester

64131

Kansas City Research Institute, Kansas City

Sponsors
All Listed Sponsors
lead

Conatus Pharmaceuticals Inc.

INDUSTRY

NCT02077374 - A Study of IDN-6556 in Subjects With NAFLD and Raised Transaminases | Biotech Hunter | Biotech Hunter